Three experts from Novalix present optimized T cell transfer-induced colitis models for IBD drug validation, utilizing AI-enhanced histology and flow cytometry to evaluate therapeutic efficacy.

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is characterized by chronic intestinal inflammation driven by immune dysregulation and impaired epithelial barrier function. To elucidate the pathogenesis of IBD, various murine models of chronic intestinal inflammation have been developed.​

Novalix offers a comprehensive range of in vivo models for inflammatory diseases, including IBD. Our portfolio features well-established models such as dextran sulfate sodium (DSS)-induced colitis and T cell transfer-induced colitis, both of which closely mimic the clinical pathology observed in humans.​

We have successfully implemented the traditional 53-day T cell transfer model to support the validation of novel therapeutic approaches. To improve efficiency while preserving translational relevance, we have further developed a shorter optimized 35-day version of this model. By incorporating IL12/23p40, we have enabled a 35-day model that is ideal for evaluating new drug candidates. In this model, disease progression is monitored using the disease activity index and artificial intelligence-enhanced histology. Additionally, the mechanism of action of test compounds can be elucidated through flow cytometry analysis of macrophages and dendritic cells isolated from the colon.

Key Topics:

• Gain an overview of Novalix's in vivo portfolio with a focus on in vivo inflammatory bowel disease (IBD) and inflammatory disease​


• Understand key pathophysiological features of IBD and the murine T cell transfer colitis model​


• Learn how AI-enhanced histology supports robust and quantitative tissue analysis​


• Explore the use of flow cytometry to investigate immune mechanisms of action